bpc-157 tga approval australia A health warning about unregulated peptides has been issued by Australia's drug regulator but doctors say more action is needed. Reporting by national health equity reporters Caitlyn Gribbin and Rachel Carbonell, ABC Lupin gets Australian TGA approval

Kidney outcomes with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas in type 2 diabetes and moderate cardiovascular risk

Developed by researchers in Australia, AOD-9604 was initially investigated as a potential anti-obesity drug due to its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat accumulation)

See Table 68 for final CY 2026 SI and APC assignments for specific HCPCS codes in the series and Table 69 for the final CY 2026 Neurostimulator and Related Procedures APCs

BPC 157 is being used both orally and by injection in research and clinical care, and is thought to be stable in our intestinal environment

Kamata, H., Manabe, T., Oka, S., Kamata, K

While both treatments support overall health, vitamin injections are ideal for targeted supplementation, whereas IV therapy is typically used for more comprehensive nutrient support and hydration